Movement Alert|SKB BIO Falls 3.04% in Regular Trading, Shares Remain Under Pressure Despite Target Price Increase

Market Focus11-16

On November 16, SKB BIO fell 3.04% in Regular Trading, trading at HK$434.4, with turnover of HK$62.10 million.

The clearest recent catalyst is an investment-bank update: a major broker raised its target price to HK$645.62 and maintained a Buy rating, but the positive call did not prevent the stock from remaining under near-term selling pressure.

According to the published note, the target price was lifted from HK$642.99 to HK$645.62 based on DCF, reflecting smooth progress in sac-TMT development. Near-term catalysts cited included the ASCENT-GYN readout around year-end, approval progress for sac-TMT in endometrial cancer, additional TroFuse Phase III data, and a planned Phase III study combining MK-2010 with sac-TMT. Even so, the latest trading suggests the rating upgrade has not offset short-term weakness in the name.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment